Papillary Renal Cell Carcinoma Type 2
3 clinical trials · Condition
◉ Watch Papillary Renal Cell Carcinoma Type 2
| Record | Firm | Date |
|---|---|---|
| Axitinib +/- Pembrolizumab in First Line Treatment of mPRCC (NCT05096390) | Centre Leon Berard | 2022-06-01 |
| ANZUP - Non-clear Cell Post Immunotherapy CABozantinib (UNICAB) (NCT03685448) | Australian and New Zealand Urogenital and Prostate Cancer Trials Group | 2019-04-11 |
| Phase II Sequential Treatment Trial of Single Agent Nivolumab, Then Combination Ipilimumab + Nivolumab in Metastatic or Unresectable Non-Clear Cell Renal Cell Carcinoma (ANZUP1602) (NCT03177239) | Australian and New Zealand Urogenital and Prostate Cancer Trials Group | 2017-10-19 |
Track Papillary Renal Cell Carcinoma Type 2 automatically
Every clearance here is in the API, with alerts when new ones post.